Biotech Values

[AlpineBV_Miller]

There may be a demand issue, but what Dendreon is experiencing now has nothing to do with demand. End users who REALLY push their urologist are being referred out to academic centers and getting treated. The average patient accepts the urologist's claim he is being put on a waiting list.

Expect Dendreon to partner with certain practices to create "Provenge - No Waiting" ads in select markets, or the practices to do it themselves.

We can argue about whether the market demand exists, but saying "cost density" is a dmeand issue confuses an already confusing point.